Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
E. coli Nissle ΔclbP
- Development stage
- Preclinical
- Lead developer
- Ardeypharm
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
E. coli Nissle ΔclbP is a genetically modified version of the probiotic strain *Escherichia coli* Nissle 1917 (EcN). The modification involves the deletion of the *clbP* gene, which encodes a peptidase essential for the maturation of colibactin, a genotoxic secondary metabolite produced by the *pks* genomic island. While wild-type EcN is widely used for gastrointestinal disorders, its potential to induce DNA double-strand breaks via colibactin has raised safety concerns regarding long-term use and colorectal cancer risk. The ΔclbP variant retains the probiotic benefits of the parent strain—such as competitive exclusion of pathogens, enhancement of intestinal barrier function, and immunomodulation—while eliminating genotoxicity. This strain serves as a safer chassis for the development of engineered live biotherapeutic products (LBPs) designed to deliver therapeutic payloads to the gut.
- Other names
- Escherichia coli strain Nissle 1917 clbP deletion mutantclbP-deficient E. coli Nissle 1917
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))IL10 (Interleukin-10)OCLN (Occludin)
Beyond the preview
Go deeper on E. coli Nissle ΔclbP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E. coli Nissle ΔclbP.